These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 29684563)
1. Long-Term Results of Prophylactic Donor Lymphocyte Infusions for Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation. Gröger M; Gagelmann N; Wolschke C; von Pein UM; Klyuchnikov E; Christopeit M; Zander A; Ayuk F; Kröger N Biol Blood Marrow Transplant; 2018 Jul; 24(7):1399-1405. PubMed ID: 29684563 [TBL] [Abstract][Full Text] [Related]
2. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia. Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716 [TBL] [Abstract][Full Text] [Related]
3. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218 [TBL] [Abstract][Full Text] [Related]
4. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K Blood; 2001 Aug; 98(4):934-9. PubMed ID: 11493435 [TBL] [Abstract][Full Text] [Related]
5. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. Lokhorst HM; Schattenberg A; Cornelissen JJ; van Oers MH; Fibbe W; Russell I; Donk NW; Verdonck LF J Clin Oncol; 2000 Aug; 18(16):3031-7. PubMed ID: 10944138 [TBL] [Abstract][Full Text] [Related]
6. Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained. Caldemeyer LE; Akard LP; Edwards JR; Tandra A; Wagenknecht DR; Dugan MJ Biol Blood Marrow Transplant; 2017 Nov; 23(11):1989-1997. PubMed ID: 28712934 [TBL] [Abstract][Full Text] [Related]
7. Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT. Xuan L; Fan Z; Zhang Y; Zhou H; Huang F; Dai M; Nie D; Lin D; Xu N; Guo X; Jiang Q; Sun J; Xiao Y; Liu Q Oncotarget; 2016 May; 7(22):32579-91. PubMed ID: 27081039 [TBL] [Abstract][Full Text] [Related]
8. Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma. Giaccone L; Evangelista A; Patriarca F; Sorasio R; Pini M; Carnevale-Schianca F; Festuccia M; Brunello L; Zallio F; Maffini E; Omedé P; Bringhen S; Mordini N; Fanin R; Ciccone G; Boccadoro M; Bruno B Biol Blood Marrow Transplant; 2018 Jan; 24(1):189-193. PubMed ID: 28987930 [TBL] [Abstract][Full Text] [Related]
9. Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study. Zhang R; Wang L; Chen P; Gao X; Wang S; Li F; Dou L; Gao C; Li Y; Liu D Cancer Med; 2021 May; 10(10):3165-3176. PubMed ID: 33932107 [TBL] [Abstract][Full Text] [Related]
10. [Prophylactic G-CSF mobilized donor lymphocytes infusion after non-myeloablative stem cell transplantation prevents relapse in patients with high-risk leukemia]. Zhao HX; Sun WJ; Li J; Qiao JX; Huang YJ; Hu HL; Ai HS Zhonghua Xue Ye Xue Za Zhi; 2013 Nov; 34(11):922-5. PubMed ID: 24294845 [TBL] [Abstract][Full Text] [Related]
11. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E; Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175 [TBL] [Abstract][Full Text] [Related]
12. Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT. Liu L; Chang YJ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ Biol Blood Marrow Transplant; 2018 Jul; 24(7):1350-1359. PubMed ID: 29649617 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia. Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy of donor lymphocyte infusion in patients after different types of allogeneic hematopoietic stem cell transplantation]. Slesarchuk OA; Babenko EV; Semenova EV; Bondarenko SN; Éstrina MA; Morozova EV; Paina OV; Vavilov VN; Smirnov BI; Zubarovskaia LS; Afanas'ev BV Ter Arkh; 2013; 85(7):26-33. PubMed ID: 24137944 [TBL] [Abstract][Full Text] [Related]
19. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285 [TBL] [Abstract][Full Text] [Related]
20. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Klyuchnikov E; Holler E; Bornhäuser M; Kobbe G; Nagler A; Shimoni A; Könecke C; Wolschke C; Bacher U; Zander AR; Kröger N Br J Haematol; 2012 Oct; 159(2):172-81. PubMed ID: 22909192 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]